As the activity status of LTCCs is related to the risk of various malignant arrhythmias, such as timothy syndrome (TS) 13–16, modulating PLM phosphorylation might be a potential strategy for preventing and treating arrhythmias. The gene discussed is FXYD1; the disease is Timothy syndrome.